Phospho-CSF1R (Tyr561) Antibody

What is Phospho-CSF1R (Tyr561) Antibody and what does it detect?

Phospho-CSF1R (Tyr561) antibody specifically detects endogenous levels of Colony Stimulating Factor-1 Receptor (CSF1R) only when phosphorylated at tyrosine residue 561. CSF1R is a transmembrane receptor tyrosine kinase that mediates the biological effects of CSF1 (M-CSF), a cytokine which controls the production, differentiation, and function of macrophages . This receptor, also known as CD115 or c-Fms, plays critical roles in myeloid cell development and function . The antibody binds to the phosphorylated form of the receptor, serving as a valuable tool for studying CSF1R activation status in various experimental contexts .

What are the common applications for Phospho-CSF1R (Tyr561) Antibody?

Phospho-CSF1R (Tyr561) antibodies are validated for multiple research applications:

Most commercially available antibodies are supplied as unconjugated reagents, though they can be paired with appropriate secondary detection systems including HRP, AP, biotin, or fluorescent conjugates for visualization .

What species reactivity can be expected with Phospho-CSF1R (Tyr561) Antibody?

Most commercial Phospho-CSF1R (Tyr561) antibodies show reactivity with human, mouse, and rat samples due to the high conservation of the phosphorylation site across these species . The immunogen typically used for generating these antibodies is a synthetic peptide derived from human CSF1R around the phosphorylation site of Tyr561, usually spanning amino acids 531-580 . When conducting cross-species experiments, it is advisable to verify the sequence homology in the region surrounding the Tyr561 residue to ensure antibody recognition .

What is the optimal storage condition for Phospho-CSF1R (Tyr561) Antibody?

For maximum stability and retention of activity, Phospho-CSF1R (Tyr561) antibodies should be stored at -20°C for up to 1 year from the date of receipt . Most commercial preparations are supplied in PBS (pH 7.4) containing 50% glycerol, sometimes with additional stabilizers such as 0.5% BSA, and 0.02% sodium azide as a preservative . Upon receipt, it is recommended to aliquot the antibody into smaller volumes to minimize freeze-thaw cycles, which can degrade the antibody and reduce its effectiveness . Working dilutions should be prepared fresh and can typically be stored at 4°C for up to one week.

What is the significance of Tyr561 phosphorylation in CSF1R function?

Tyr561 phosphorylation represents a critical event in CSF1R signaling and function. Upon binding of CSF1 or IL34 to CSF1R, receptor dimerization occurs, followed by transphosphorylation of tyrosine residues . Notably, Tyr561 is the first tyrosine to be phosphorylated and is necessary for full receptor activation . This phosphorylation site serves several important functions:

• It is crucial for normal down-regulation of signaling through ubiquitination, internalization, and degradation of the receptor .

• It creates a docking site for SRC family kinases (including FYN, YES1, and SRC), facilitating their interaction with and subsequent activation by CSF1R .

• It contributes to the initiation of downstream signaling cascades that promote macrophage proliferation, differentiation, and survival .

Mutations or dysregulation affecting this phosphorylation site can potentially disrupt normal CSF1R signaling, which has implications for various pathological conditions, including neurodegenerative disorders and certain malignancies .

What positive controls are recommended for Phospho-CSF1R (Tyr561) Antibody validation?

When validating Phospho-CSF1R (Tyr561) antibodies, several positive controls have been established in the literature:

• HepG2 cells treated with PMA (phorbol 12-myristate 13-acetate) show detectable levels of phosphorylated CSF1R at Tyr561 and serve as an excellent positive control for Western blot applications .

• Human brain tissue sections have been successfully used as positive controls for immunohistochemistry applications, showing specific staining that can be blocked with the appropriate phosphopeptide .

• Macrophage cell lines (such as RAW264.7) or bone marrow-derived macrophages stimulated with CSF1/M-CSF (50-100 ng/ml for 5-10 minutes) exhibit robust Tyr561 phosphorylation .

For negative controls, the same samples without stimulation or treated with CSF1R kinase inhibitors can be used, as well as conducting the primary antibody incubation in the presence of a blocking phosphopeptide .

How can I validate the specificity of Phospho-CSF1R (Tyr561) Antibody in my experiments?

Rigorous validation of phospho-specific antibodies is crucial for reliable results. For Phospho-CSF1R (Tyr561) antibody, employ these complementary approaches:

• Blocking peptide competition:
  Compare antibody staining with and without pre-incubation with a synthetic phosphopeptide containing the Tyr561 site. Immunohistochemical analysis of human brain tissue has demonstrated that pre-incubation with a blocking peptide abolishes specific staining, confirming antibody specificity .

• Phosphatase treatment:
  Divide your sample and treat one portion with lambda phosphatase before immunoblotting. The phosphatase-treated sample should show diminished or absent signal compared to the untreated sample.

• Stimulation/inhibition experiments:
  Analyze samples with and without treatments known to induce CSF1R phosphorylation (e.g., CSF1/M-CSF stimulation) or inhibit it (e.g., CSF1R-specific kinase inhibitors).

• siRNA knockdown or CRISPR knockout:
  Reduce or eliminate CSF1R expression using genetic approaches and confirm reduction in antibody signal.

• Mutant controls:
  If possible, use cells expressing a Y561F mutant version of CSF1R, which cannot be phosphorylated at this site, as a negative control.

Document all validation steps meticulously, as they strengthen the credibility of subsequent experimental findings.

What are the best sample preparation methods for detecting phosphorylated CSF1R?

Phosphorylation states are notoriously labile and require careful sample handling to preserve. For optimal detection of phosphorylated CSF1R at Tyr561:

For Western Blotting:

• Rapidly lyse cells in buffer containing both phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) and protease inhibitors.

• Maintain samples at 4°C throughout processing.

• Add phosphatase inhibitors to all buffers used in sample preparation.

• Use SDS-PAGE gels with appropriate percentage (typically 7.5-10%) to resolve the ~107 kDa CSF1R protein effectively .

• Transfer to PVDF membrane (preferred over nitrocellulose for phosphoproteins).

For Immunohistochemistry:

• Fix tissues rapidly after collection (ideally within minutes).

• For paraffin embedding, use 10% neutral buffered formalin fixation for no more than 24 hours.

• Include phosphatase inhibitors in the fixative solution when possible.

• For antigen retrieval, heat-induced epitope retrieval using citrate buffer (pH 6.0) has shown good results with these antibodies .

For Cell-Based ELISA and Immunofluorescence:

• Cells should be fixed while still adherent to preserve signaling states.

• Brief fixation (10-15 minutes) with 4% paraformaldehyde is typically optimal.

• Permeabilization with 0.1-0.3% Triton X-100 allows antibody access to intracellular epitopes without excessive disruption of phosphoepitopes.

How do mutations in CSF1R affect Tyr561 phosphorylation and what are the implications for disease research?

CSF1R mutations have significant implications for both phosphorylation status and disease pathogenesis. Research utilizing Phospho-CSF1R (Tyr561) antibodies has revealed:

CSF1R-related disorders (CSF1R-RD) represent a spectrum of devastating neurodegenerative conditions caused by variants in the CSF1R gene . These disorders lead to variable combinations of cognitive impairment, movement disorders, and upper motor neuron signs, with associated white matter abnormalities visible on brain imaging . While traditionally considered rare, recent analysis of the UK Biobank whole-exome sequencing data (N=470,000) suggests that pathogenic and likely pathogenic CSF1R variants may be more common in the general population than previously recognized .

Specific mutations affecting the tyrosine kinase domain of CSF1R, including those in proximity to Tyr561, can disrupt normal phosphorylation patterns . Mutations at codon 301 (L301S) have been identified in some patients with Acute Myeloid Leukemia (AML) and are believed to contribute to constitutive activation of the receptor . Conversely, mutations affecting regulatory phosphorylation sites can lead to aberrant signaling by preventing normal feedback mechanisms.

Researchers investigating these diseases should consider:

• Comparing phosphorylation patterns in patient-derived samples versus healthy controls using Phospho-CSF1R (Tyr561) antibodies.

• Developing cell models expressing disease-specific CSF1R mutations to assess phosphorylation status.

• Correlating phosphorylation states with disease severity or progression.

• Using phosphorylation status as a biomarker for therapeutic efficacy in emerging treatments.

What are the key downstream signaling pathways activated following Tyr561 phosphorylation?

Tyr561 phosphorylation initiates a complex cascade of signaling events with far-reaching cellular consequences. The key pathways include:

• SRC Family Kinase Activation: Phosphorylation at Tyr561 creates a docking site for SRC family kinases (SRC, FYN, YES1), leading to their activation . This interaction is critical for subsequent signaling events.

• PI3K/Akt Pathway: Studies analyzing CSF1R-mutations in macrophages suggest that the PI3K/Akt pathway has a pivotal role in ensuring CSF1-mediated survival of macrophages . Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to activation of the AKT1 signaling pathway .

• MAPK Pathways: Activated CSF1R mediates activation of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1 . This pathway is particularly important for proliferative responses.

• STAT Activation: CSF1R signaling promotes activation of STAT family members STAT3, STAT5A, and/or STAT5B .

• Negative Regulation: Receptor signaling is down-regulated by protein phosphatases, such as INPP5D/SHIP-1, that dephosphorylate the receptor and its downstream effectors, and by rapid internalization of the activated receptor .

Understanding these pathways is essential for interpreting experimental results using Phospho-CSF1R (Tyr561) antibodies, particularly when investigating the effects of therapeutic compounds targeting CSF1R signaling.

How can I develop a quantitative assay for measuring CSF1R Tyr561 phosphorylation?

For quantitative assessment of CSF1R Tyr561 phosphorylation, several methodological approaches are available:

• Cell-Based ELISA:
  The CSFR (Phospho-Tyr561) Colorimetric Cell-Based ELISA Kit provides a convenient, lysate-free, high-throughput method . This approach uses:

  • CSFR (Phospho-Tyr561)-specific primary antibodies

  • HRP-conjugated secondary antibodies

  • Multiple normalization methods:
    a) GAPDH antibody as an internal positive control
    b) Crystal Violet whole-cell staining for cell density normalization

• Quantitative Western Blotting:
  For precise quantification via Western blot:

  • Use a dual-detection approach with separate antibodies against phosphorylated and total CSF1R

  • Calculate the phospho/total ratio to normalize for differences in total protein expression

  • Include a concentration curve of reference standards

  • Use digital imaging systems with appropriate software for densitometric analysis

  • Always work within the linear dynamic range of detection

• Phospho-Flow Cytometry:
  For single-cell resolution:

  • Fix and permeabilize cells (methanol-based protocols often work well for phospho-epitopes)

  • Stain with Phospho-CSF1R (Tyr561) antibody followed by fluorophore-conjugated secondary antibody

  • Include markers for relevant cell populations

  • Measure mean fluorescence intensity as indicator of phosphorylation level

• Quantitative Immunofluorescence:

  • Stain fixed cells with Phospho-CSF1R (Tyr561) antibody

  • Include counterstains for total CSF1R and nuclear marker

  • Capture images using consistent exposure settings

  • Quantify intensity using image analysis software

  • Express results as ratio of phospho-CSF1R to total CSF1R signal

For all approaches, include appropriate positive controls (CSF1-stimulated cells) and negative controls (unstimulated or inhibitor-treated cells), and perform experiments in at least triplicate for statistical validity.

What optimization strategies can improve detection sensitivity for low expression levels of phosphorylated CSF1R?

When dealing with samples where phosphorylated CSF1R is expressed at low levels, several optimization strategies can significantly improve detection sensitivity:

• Signal Amplification Methods:

  • Implement tyramide signal amplification (TSA) for IHC or IF applications

  • Use biotin-streptavidin systems for multiple layers of signal enhancement

  • Consider polymer-based detection systems with higher sensitivity than traditional secondary antibodies

• Sample Enrichment Techniques:

  • Perform phosphoprotein enrichment using titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC)

  • Use immunoprecipitation with total CSF1R antibodies before Western blotting with phospho-specific antibody

  • For cell populations, consider FACS-based enrichment of CSF1R-positive cells before analysis

• Protocol Optimization:

  • Extend primary antibody incubation time (overnight at 4°C often improves signal-to-noise ratio)

  • Optimize blocking buffers to reduce background while preserving specific signal

  • Test different antigen retrieval methods for IHC (citrate vs. EDTA buffers, microwave vs. pressure cooker)

  • For Western blots, use gradient gels to improve resolution and transfer efficiency

• Maximizing Phosphorylation Status:

  • Treat cells with phosphatase inhibitors before lysis (calyculin A is particularly effective)

  • Optimize stimulation conditions (concentration and timing) with CSF1 or IL-34

  • Consider pre-treatment with hydrogen peroxide to transiently inactivate phosphatases

  • Minimize time between sample collection and fixation/lysis

• Alternative Detection Methods:

  • Consider proximity ligation assay (PLA) which can detect single phosphorylation events with high specificity

  • Explore more sensitive detection reagents such as quantum dots or near-infrared fluorophores

  • For extremely low abundance, consider MS-based phosphoproteomics approaches

Document all optimization steps methodically to identify the combination of approaches that works best for your specific experimental system.

How can Phospho-CSF1R (Tyr561) Antibody be used to screen potential therapeutic compounds?

Phospho-CSF1R (Tyr561) antibodies are valuable tools for screening compounds that modulate CSF1R signaling, with applications in drug discovery for inflammatory disorders, cancer, and neurodegenerative diseases:

• High-Throughput Screening Approaches:

  • Cell-based ELISA platforms allow screening of large compound libraries for effects on Tyr561 phosphorylation

  • Establish dose-response relationships by testing compounds across concentration ranges

  • Multiplex with cell viability assays to distinguish between pathway inhibition and cytotoxicity

  • Develop automated image-based screening using phospho-CSF1R immunofluorescence

• Mechanistic Studies:

  • Determine if compounds directly inhibit CSF1R kinase activity or act on upstream/downstream signaling components

  • Assess effects on receptor internalization and degradation, which are influenced by Tyr561 phosphorylation

  • Characterize temporal dynamics of inhibition using time-course experiments

  • Investigate potential compensatory mechanisms that emerge following CSF1R inhibition

• Translational Research Applications:

  • Test compounds in patient-derived cells to predict personalized responses

  • Correlate in vitro phosphorylation changes with in vivo efficacy in disease models

  • Develop phospho-CSF1R as a pharmacodynamic biomarker for clinical trials

  • Evaluate combination therapies targeting CSF1R and complementary pathways

• Practical Implementation in Drug Screening:

  • Establish robust positive controls (e.g., known CSF1R inhibitors) and negative controls

  • Include internal standards to ensure inter-assay comparability

  • Normalize phospho-CSF1R signal to total CSF1R levels

  • Consider counter-screening against related receptors to assess specificity

Current clinical interest in CSF1R inhibition is evidenced by ongoing trials, such as a phase 2 trial of a fully humanized agonist TREM2 monoclonal antibody for CSF1R-related disorders (ClinicalTrials.gov ID NCT05677659) . Phospho-CSF1R (Tyr561) antibodies provide critical tools for developing and evaluating such therapeutic approaches.

What are the considerations for using Phospho-CSF1R (Tyr561) Antibody in multiplex immunofluorescence studies?

Multiplex immunofluorescence incorporating Phospho-CSF1R (Tyr561) antibody allows simultaneous visualization of CSF1R activation alongside other biomarkers, providing rich contextual data. Key considerations include:

• Antibody Compatibility:

  • Determine whether primary antibodies are raised in different host species to avoid cross-reactivity

  • If antibodies are from the same host, consider directly conjugated primary antibodies or sequential staining protocols

  • Test antibody panels on control samples to ensure individual staining patterns are maintained in multiplex format

  • Validate that phospho-specificity is preserved in multiplex conditions

• Spectral Considerations:

  • Choose fluorophores with minimal spectral overlap

  • Consider brightness hierarchy: assign brighter fluorophores to less abundant targets

  • Include single-stain controls for spectral unmixing and compensation

  • Evaluate potential issues with tissue autofluorescence, particularly in brain or macrophage-rich tissues

• Technical Protocol Optimization:

  • Determine optimal fixation that preserves all antigens of interest while maintaining phospho-epitopes

  • Test different antigen retrieval methods if epitopes require different conditions

  • Optimize blocking to minimize background while preserving specific signals

  • Consider tyramide signal amplification (TSA) for detecting low-abundance phospho-epitopes

• Analysis Approaches:

  • Implement automated image analysis pipelines for consistent quantification

  • Use nuclear counterstain to facilitate cell segmentation

  • Develop clear rules for classifying cells as positive or negative for each marker

  • Consider spatial relationship analyses to understand the microenvironmental context of CSF1R activation

• Suggested Marker Combinations:

  • For macrophage studies: Phospho-CSF1R (Tyr561) + CD68 (macrophage marker) + phospho-ERK1/2 (downstream signaling)

  • For neurological disorders: Phospho-CSF1R (Tyr561) + IBA1 (microglia marker) + GFAP (astrocytes) + MBP (myelin)

  • For tumor microenvironment: Phospho-CSF1R (Tyr561) + CD163 (M2 macrophages) + CD8 (cytotoxic T cells) + pan-Cytokeratin (tumor cells)

By addressing these considerations, researchers can develop robust multiplex protocols that provide comprehensive insights into CSF1R signaling within complex cellular contexts.